{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137"}]}],"title":"Any Grade AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"136"}]}],"title":"Grade 3 or 4 AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"98"}]}],"title":"SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"136"}]}],"title":"AEs of Special Interest"},{"categories":[{"measurements":[{"groupId":"OG000","value":"116"}]}],"title":"Cytokine Release Syndrome"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"}]}],"title":"Neurotoxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95"}]}],"title":"Infections"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Clinically Significant Laboratory Abnormalities"}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"}],"units":"Participants"}],"description":"Number of participants with adverse events (AEs), adverse events of special interest (AESI), serious adverse events (SAEs), cytokine release syndrome, neurotoxicity, infection and clinically signifcant laboratory abnormalities.","groups":[{"description":"BB2121","id":"OG000","title":"BB2121"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Participants","reportingStatus":"POSTED","timeFrame":"From screening to the end of follow up (approximately 5 years and 2 months)","title":"Number of Participants With Safety Related Events","type":"SECONDARY","unitOfMeasure":"Participants"}